Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing

Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. We performed a prospective study of intestinal permeability, measured by end...

Full description

Saved in:
Bibliographic Details
Published inGastroenterology (New York, N.Y. 1943) Vol. 153; no. 3; pp. 723 - 731.e1
Main Authors Chang, Jeff, Leong, Rupert W., Wasinger, Valerie C., Ip, Matthew, Yang, Michael, Phan, Tri Giang
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn’s disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0–1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis. Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008). In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752).
AbstractList Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn’s disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0–1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis. Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008). In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752).
Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms.BACKGROUND & AIMSMany patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms.We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0-1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis.METHODSWe performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy individuals [controls]) in Sydney, Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0-1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS; range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic analysis.Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008).RESULTSOngoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD, 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3; P < .001) or controls (5.9, P < .001). There were no significant differences between patients with IBD in remission vs controls (P = .261). Median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1; P = .009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the receiver operating characteristic area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day (P = .008).In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752).CONCLUSIONSIn a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB (ANZCTR.org.au: ACTRN12613001248752).
Abstract Background & Aims Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether impaired intestinal permeability contributes to these symptoms. Methods We performed a prospective study of intestinal permeability, measured by endoscopic confocal laser endomicroscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn’s disease [CD], and 22 healthy individuals [controls]) in Sydney Australia from May 2009 and September 2015. Symptomatic CD was defined by a CD Activity Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more. Mucosal healing was defined as CD Endoscopic Index of Severity of 0 in CD or Mayo endoscopic sub-score of 0–1 for patients with UC. Intestinal permeability was quantified by the Confocal Leak Score (CLS, range: 0=no impaired permeability to 100=complete loss of barrier function). The primary endpoint was intestinal permeability in patients with symptomatic IBD in mucosal healing vs patients with asymptomatic IBD in mucosal healing. We determined the sensitivity and specificity of CLS in determining symptoms based on receiver operating characteristic (ROC) analysis. Results Ongoing bowel symptoms were present in 16.3% of patients with IBD and mucosal healing (15.4% of patients with CD and 17.4% with UC). Patients with symptomatic IBD had a significantly higher median CLS (19.0) than patients with asymptomatic IBD (7.3, P <.001) or controls (5.9, P <.001). There were no significant differences between patients with IBD in remission vs controls ( P =.261). The median CLS was significantly higher in patients with symptomatic than asymptomatic CD (17.7 vs 8.1, P =.009) and patients with symptomatic than asymptomatic UC (22.2 vs 6.9, P =.021). A CLS of 13.1 or more identified ongoing bowel symptoms in patients with IBD and mucosal healing with 95.2% sensitivity and 97.6% specificity; the ROC area under curve value was 0.88. Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased intestinal permeability. On regression analysis, every increase in CLS of 1.9 correlated with an additional diarrheal motion per day ( P =.008). Conclusions In a prospective study of intestinal permeability in patients with IBD and mucosal healing, we associated impaired intestinal permeability with ongoing bowel symptoms ; increases in permeability correlated with increased severity of diarrhea. Resolution of mucosal permeability beyond mucosal healing might improve outcomes of patients with IDB. ANZCTR.org.au: ACTRN12613001248752
Author Chang, Jeff
Leong, Rupert W.
Phan, Tri Giang
Ip, Matthew
Yang, Michael
Wasinger, Valerie C.
Author_xml – sequence: 1
  givenname: Jeff
  surname: Chang
  fullname: Chang, Jeff
  organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia
– sequence: 2
  givenname: Rupert W.
  orcidid: 0000-0001-5944-3488
  surname: Leong
  fullname: Leong, Rupert W.
  email: rupertleong@outlook.com
  organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia
– sequence: 3
  givenname: Valerie C.
  surname: Wasinger
  fullname: Wasinger, Valerie C.
  organization: Bioanalytical Mass Spectrometry Facility, UNSW Australia, Sydney, Australia
– sequence: 4
  givenname: Matthew
  surname: Ip
  fullname: Ip, Matthew
  organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia
– sequence: 5
  givenname: Michael
  surname: Yang
  fullname: Yang, Michael
  organization: Gastroenterology and Liver Services, Bankstown Hospital, South Western Sydney Local Health District, Sydney, Australia
– sequence: 6
  givenname: Tri Giang
  orcidid: 0000-0002-4909-2984
  surname: Phan
  fullname: Phan, Tri Giang
  organization: Faculty of Medicine, UNSW Australia, Sydney, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28601482$$D View this record in MEDLINE/PubMed
BookMark eNqVUtGK1DAUDbLizq7-gUgefemYNE2bigg6ru7Ayi6s4mPIpLdjxjQZk1TpD-x3mzKjD4IswoX7kHPOJeecM3TivAOEnlKypISzF7vlVsUU_LIktFkSnqd-gBaUl6IghJYnaJFXXXAi-Ck6i3FHCGmZoI_QaSlqQitRLtDdetgrE6DDa5cgJuOUxTcQBlAbY02a8Mq7FMxmzK84eXzttt64LX7rf4LFt9OwT36I2Dh8o5IBlyL-YtLXLNdbNQwq-TAdwe9MBBUBK9fhj6P2MZ-6BGWz3GP0sFc2wpPjPkef3198Wl0WV9cf1qs3V4WuGpIK3quW1rVWqgQQVOiecV43fQesJDXTfSvaBqq-6QGIpq2ugNCNIG3JOIAW7Bw9P-jug_8-5v_KwUQN1ioHfoyStkQ0LWvLGfrsCB03A3RyH8ygwiR_e5cB1QGgg48xQP8HQomcI5I7eYhIzhFJwvPUmfbyL5o2KVs326yMvY_8-kCGbNIPA0FGnU3X0OUMdZKdN_8roLP_Riv7DSaIOz-G3IBshIylJPJ2rtDcINow3jBKs8Crfwvcf_8XS5va2A
CitedBy_id crossref_primary_10_1093_ibd_izae238
crossref_primary_10_1155_2018_3048532
crossref_primary_10_1016_j_ctrv_2022_102406
crossref_primary_10_3389_fgstr_2022_959082
crossref_primary_10_1002_bdd_2220
crossref_primary_10_4166_kjg_2022_001
crossref_primary_10_1007_s11655_022_3531_x
crossref_primary_10_1016_j_phymed_2021_153590
crossref_primary_10_3390_nu10111684
crossref_primary_10_1186_s40779_021_00341_4
crossref_primary_10_23736_S2724_5985_22_03215_6
crossref_primary_10_3390_nu10081016
crossref_primary_10_1016_j_cgh_2020_03_044
crossref_primary_10_1016_j_giec_2019_02_004
crossref_primary_10_1016_j_cgh_2018_08_001
crossref_primary_10_3390_immuno1040039
crossref_primary_10_3390_antiox9100926
crossref_primary_10_3390_molecules24030513
crossref_primary_10_1016_j_jare_2022_03_010
crossref_primary_10_1111_apt_14368
crossref_primary_10_1016_j_heliyon_2023_e22186
crossref_primary_10_1038_s41598_021_92262_4
crossref_primary_10_3390_nu16183173
crossref_primary_10_1016_j_jep_2024_118570
crossref_primary_10_3390_cells9081793
crossref_primary_10_34215_1609_1175_2019_4_5_9
crossref_primary_10_3390_ijms241512078
crossref_primary_10_3923_pjbs_2022_313_321
crossref_primary_10_1016_j_imlet_2022_07_006
crossref_primary_10_3389_fcell_2023_1223032
crossref_primary_10_3923_pjn_2021_46_54
crossref_primary_10_1016_j_jpain_2022_09_016
crossref_primary_10_1007_s11356_023_30542_4
crossref_primary_10_1021_acs_jafc_4c04933
crossref_primary_10_1038_s41598_020_71198_1
crossref_primary_10_1111_1541_4337_12652
crossref_primary_10_1126_sciadv_ado8222
crossref_primary_10_3389_fcell_2023_1132905
crossref_primary_10_1016_j_intimp_2024_111886
crossref_primary_10_1152_ajpgi_00104_2019
crossref_primary_10_1016_j_intimp_2021_108091
crossref_primary_10_1038_s41419_022_04566_6
crossref_primary_10_3390_ijms25115817
crossref_primary_10_1002_ncp_10489
crossref_primary_10_1055_a_2208_7019
crossref_primary_10_1093_abbs_gmab116
crossref_primary_10_3390_ijms231911162
crossref_primary_10_3390_ijms26062466
crossref_primary_10_1186_s12906_019_2749_4
crossref_primary_10_1016_j_micres_2024_127928
crossref_primary_10_1038_s41598_020_78141_4
crossref_primary_10_3390_diagnostics14151606
crossref_primary_10_1016_j_gastha_2023_11_005
crossref_primary_10_4291_wjgp_v11_i6_114
crossref_primary_10_1038_s41598_024_60959_x
crossref_primary_10_1016_j_ebiom_2022_103846
crossref_primary_10_1152_ajpgi_00298_2017
crossref_primary_10_1016_j_cgh_2019_09_021
crossref_primary_10_1016_j_intimp_2018_09_005
crossref_primary_10_1097_MPG_0000000000002770
crossref_primary_10_1016_j_intimp_2020_106288
crossref_primary_10_1007_s10620_023_08122_w
crossref_primary_10_1016_j_jep_2023_117503
crossref_primary_10_1016_j_cgh_2018_08_060
crossref_primary_10_1093_ibd_izy381
crossref_primary_10_1038_s41575_019_0261_4
crossref_primary_10_1016_j_immuni_2020_10_018
crossref_primary_10_1053_j_gastro_2022_07_004
crossref_primary_10_1016_j_jff_2019_103614
crossref_primary_10_1007_s13679_019_00332_6
crossref_primary_10_1136_gutjnl_2023_329964
crossref_primary_10_1038_s41684_019_0438_z
crossref_primary_10_1093_ibd_izz021
crossref_primary_10_1155_2018_5738068
crossref_primary_10_3389_fcimb_2022_1064537
crossref_primary_10_1038_s41467_021_24470_5
crossref_primary_10_3390_biom14091122
crossref_primary_10_1080_19490976_2024_2359515
crossref_primary_10_3390_cells8070719
crossref_primary_10_1042_CS20210778
crossref_primary_10_3389_fnut_2021_717925
crossref_primary_10_1016_j_jpha_2024_01_008
crossref_primary_10_22416_1382_4376_2021_31_1_20_30
crossref_primary_10_3390_app11167622
crossref_primary_10_1080_17474124_2021_1840352
crossref_primary_10_1093_ibd_izab179
crossref_primary_10_1016_j_intimp_2024_112416
crossref_primary_10_1111_den_14659
crossref_primary_10_1242_dmm_049332
crossref_primary_10_1172_JCI120261
crossref_primary_10_1016_j_molmet_2021_101183
crossref_primary_10_1186_s13287_019_1246_5
crossref_primary_10_3390_nu13020642
crossref_primary_10_3748_wjg_v29_i36_5254
crossref_primary_10_1080_14786419_2024_2435535
crossref_primary_10_1111_apt_18027
crossref_primary_10_1021_acs_jafc_9b06294
crossref_primary_10_1016_j_gie_2018_08_006
crossref_primary_10_3389_fimmu_2024_1394654
crossref_primary_10_1016_j_gastha_2024_02_003
crossref_primary_10_3389_fnut_2022_718710
crossref_primary_10_1016_j_phrs_2020_105340
crossref_primary_10_3390_ijms23136944
crossref_primary_10_1039_D3FO01095C
crossref_primary_10_3389_fimmu_2019_01441
crossref_primary_10_1038_s41584_023_00984_8
crossref_primary_10_1111_jsap_13506
crossref_primary_10_3390_proteomes6020017
crossref_primary_10_1016_j_jlr_2023_100486
crossref_primary_10_1111_jgh_16767
crossref_primary_10_1016_j_gastrohep_2021_02_022
crossref_primary_10_1042_CS20181081
crossref_primary_10_1111_apt_17241
crossref_primary_10_1093_ibd_izab239
crossref_primary_10_1186_s41232_017_0056_3
crossref_primary_10_1111_den_13023
crossref_primary_10_5056_jnm21018
crossref_primary_10_1093_ibd_izab230
crossref_primary_10_3390_nu11061239
crossref_primary_10_1186_s13256_024_05010_3
crossref_primary_10_1371_journal_ppat_1009989
crossref_primary_10_3389_fnagi_2022_861035
crossref_primary_10_1186_s12876_021_02035_6
crossref_primary_10_3390_metabo12100956
crossref_primary_10_4062_biomolther_2021_086
crossref_primary_10_1016_j_foodchem_2024_142391
crossref_primary_10_1016_j_intimp_2024_112900
crossref_primary_10_3233_NHA_170030
crossref_primary_10_1093_ecco_jcc_jjz027
crossref_primary_10_3389_fimmu_2022_895636
crossref_primary_10_1007_s10620_019_05580_z
crossref_primary_10_1016_j_isci_2020_101798
crossref_primary_10_1038_s41385_021_00380_z
crossref_primary_10_1093_ecco_jcc_jjaa085
crossref_primary_10_3389_fmed_2023_1221449
crossref_primary_10_3390_ijms24032971
crossref_primary_10_3748_wjg_v24_i6_706
crossref_primary_10_1016_j_jff_2024_106069
crossref_primary_10_1155_2021_5514075
crossref_primary_10_56871_CmN_W_2024_77_19_008
crossref_primary_10_1080_17474124_2023_2242772
crossref_primary_10_3390_microorganisms9081634
crossref_primary_10_3748_wjg_v29_i33_4991
crossref_primary_10_1016_j_gtc_2021_03_008
crossref_primary_10_1093_ibd_izae084
crossref_primary_10_1007_s10753_020_01259_0
crossref_primary_10_3390_diagnostics13071230
crossref_primary_10_1007_s10620_021_06888_5
crossref_primary_10_1016_j_actbio_2024_02_015
crossref_primary_10_1155_2018_9184093
crossref_primary_10_1093_ibd_izaf043
crossref_primary_10_1002_mnfr_202300509
crossref_primary_10_1186_s12951_022_01598_0
crossref_primary_10_3390_ijms232314776
crossref_primary_10_19110_1994_5655_2022_4_76_81
crossref_primary_10_5009_gnl220409
crossref_primary_10_1016_j_jnutbio_2021_108840
crossref_primary_10_1038_s41385_022_00550_7
crossref_primary_10_1016_j_cgh_2019_07_005
crossref_primary_10_3389_fimmu_2021_767456
crossref_primary_10_1016_j_jnutbio_2022_109254
crossref_primary_10_1177_2050640620977371
crossref_primary_10_7759_cureus_53699
crossref_primary_10_1186_s13020_024_01006_9
crossref_primary_10_1155_2022_9171436
crossref_primary_10_3390_cimb45070350
crossref_primary_10_1038_s41366_019_0492_z
crossref_primary_10_1002_mnfr_201901269
crossref_primary_10_1016_j_cell_2020_09_009
crossref_primary_10_3748_wjg_v26_i26_3712
crossref_primary_10_1016_j_jep_2023_117105
crossref_primary_10_1080_21688370_2018_1463897
crossref_primary_10_3389_fnut_2021_798038
crossref_primary_10_2147_JIR_S407521
crossref_primary_10_1002_smll_202310851
crossref_primary_10_3390_ijms23062995
crossref_primary_10_1053_j_gastro_2022_10_014
crossref_primary_10_1016_j_jss_2023_08_027
crossref_primary_10_1152_ajpgi_00198_2023
crossref_primary_10_1016_j_gastre_2021_02_007
crossref_primary_10_1016_j_ijbiomac_2024_137847
crossref_primary_10_1016_j_actbio_2022_02_039
crossref_primary_10_1039_D3TB02302H
crossref_primary_10_1177_1756284819880733
crossref_primary_10_2217_bmm_2020_0353
crossref_primary_10_1177_20420188231207348
crossref_primary_10_1016_j_msec_2018_08_033
crossref_primary_10_3390_nu13124259
crossref_primary_10_3390_ijms21051887
crossref_primary_10_1128_iai_00583_21
crossref_primary_10_3390_nu11030610
crossref_primary_10_14309_ajg_0000000000000183
crossref_primary_10_5817_CSF2023_5_233
crossref_primary_10_1021_acsami_3c14113
crossref_primary_10_1111_cpr_12547
crossref_primary_10_1177_1756284818769076
crossref_primary_10_1111_jcmm_14457
crossref_primary_10_3389_fphar_2020_594847
crossref_primary_10_1016_j_ijbiomac_2024_138122
crossref_primary_10_1016_j_jcmgh_2021_05_003
crossref_primary_10_1002_mnfr_202100639
crossref_primary_10_1016_j_gie_2018_02_038
crossref_primary_10_1039_D0NR00465K
crossref_primary_10_3389_fphar_2022_883918
crossref_primary_10_1097_j_pain_0000000000002096
crossref_primary_10_1152_ajpgi_00159_2024
crossref_primary_10_1016_j_jcmgh_2021_01_020
Cites_doi 10.3109/00365529709025101
10.1016/S0002-9270(01)04037-0
10.1136/gutjnl-2012-304066
10.1053/j.gastro.2013.06.010
10.1038/ncpgasthep0528
10.1097/MCG.0b013e3181fbdb8a
10.7869/tg.2012.3
10.1136/gut.47.3.404
10.1016/j.gie.2015.08.045
10.1038/ajg.2012.260
10.1097/MIB.0000000000000921
10.1136/gutjnl-2012-302093
10.1053/j.gastro.2014.07.046
10.1136/gutjnl-2011-300695
10.1038/nrgastro.2010.83
10.1002/ibd.20539
10.1016/j.cgh.2013.07.001
10.1016/j.dld.2015.01.148
10.1111/j.1572-0241.2002.05914.x
10.1016/j.gie.2013.04.042
10.1016/j.cgh.2012.02.029
10.1097/01.MIB.0000195385.19268.68
10.1016/j.crohns.2011.10.004
10.1038/ajg.2009.545
10.1111/apt.12262
10.1002/ibd.20520
10.1002/ibd.21925
10.1111/j.1365-2982.2012.01928.x
10.1053/j.gastro.2008.08.054
10.1038/ajg.2010.156
ContentType Journal Article
Copyright 2017 AGA Institute
AGA Institute
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2017 AGA Institute
– notice: AGA Institute
– notice: Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1053/j.gastro.2017.05.056
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1528-0012
EndPage 731.e1
ExternalDocumentID 28601482
10_1053_j_gastro_2017_05_056
S0016508517357311
1_s2_0_S0016508517357311
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
1B1
1CY
1P~
1~5
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
AAEDT
AAEDW
AAFWJ
AAIKJ
AALRI
AAQFI
AAQOH
AAQQT
AAQXK
AAXUO
ABCQX
ABDPE
ABJNI
ABLJU
ABMAC
ABOCM
ABWVN
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AENEX
AEVXI
AFFNX
AFHKK
AFJKZ
AFRHN
AFTJW
AGCQF
AGHFR
AGQPQ
AI.
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BELOY
BR6
C5W
CAG
COF
CS3
DU5
EBS
EFJIC
EFKBS
EJD
F5P
FD8
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M41
MO0
N4W
N9A
NQ-
O9-
OC.
OHT
ON0
P2P
PC.
QTD
R2-
ROL
RPZ
SEL
SES
SJN
SSZ
UDS
UGJ
UV1
VH1
WH7
X7M
XH2
Y6R
YQJ
Z5R
ZGI
ZXP
AAYOK
ADPAM
AFCTW
PKN
RIG
AAIAV
AGZHU
AHPSJ
ALXNB
G8K
TWZ
ZA5
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c470t-5fa9166caa2ee818cf35567fde32063cf9897e4f7fee0c19c4e01b809235eec83
ISSN 0016-5085
1528-0012
IngestDate Fri Jul 11 16:03:12 EDT 2025
Wed Feb 19 02:40:26 EST 2025
Tue Jul 01 02:08:58 EDT 2025
Thu Apr 24 23:04:13 EDT 2025
Fri Feb 23 02:41:20 EST 2024
Sun Feb 23 10:19:21 EST 2025
Tue Aug 26 20:03:19 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords CRP
Intestinal Barrier Function
CD
ESR
NSAID
IBD
CLS
IQR
TNF
UC
Leaky Gut
eCLE
IBS
CLE
Small Intestine
C-reactive protein
intestinal barrier function
FL
fluorescein leak
endoscope based confocal laser endomicroscopy
CDO
CDAI
Crohn's disease activity index
Crohn's disease endoscopic index score
inter-quartile range
ulcerative colitis
receiver operating characteristic
leaky gut
erythrocyte sedimentation rate
irritable bowel syndrome
ROC
partial Mayo
Crohn's disease
Confocal Leak Score
inflammatory bowel disease
cell junction enhancement
pMayo
tumor necrosis factor
small intestine
cell drop out
CDEIS
CJE
Language English
License Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c470t-5fa9166caa2ee818cf35567fde32063cf9897e4f7fee0c19c4e01b809235eec83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4909-2984
0000-0001-5944-3488
PMID 28601482
PQID 1908793928
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1908793928
pubmed_primary_28601482
crossref_primary_10_1053_j_gastro_2017_05_056
crossref_citationtrail_10_1053_j_gastro_2017_05_056
elsevier_sciencedirect_doi_10_1053_j_gastro_2017_05_056
elsevier_clinicalkeyesjournals_1_s2_0_S0016508517357311
elsevier_clinicalkey_doi_10_1053_j_gastro_2017_05_056
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-09-01
PublicationDateYYYYMMDD 2017-09-01
PublicationDate_xml – month: 09
  year: 2017
  text: 2017-09-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Gastroenterology (New York, N.Y. 1943)
PublicationTitleAlternate Gastroenterology
PublicationYear 2017
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References McGuckin, Eri, Simms (bib8) 2009; 15
Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0; Mar 2011; Available at
Schoepfer, Beglinger, Straumann (bib26) 2010; 105
Ballegaard, Bjergstrøm, Brøndum (bib4) 1997; 32
Leong, Nguyen, Meredith (bib19) 2008; 135
Fritscher-Ravens, Schuppan, Ellrichmann (bib9) 2014; 147
Vivinus-Nébot, Frin-Mathy, Bzioueche (bib20) 2014; 63
Chang, Ip, Yang (bib15) 2016; 83
Lewis, Chuai, Nessel (bib28) 2008; 14
Simrén, Axelsson, Gillberg (bib32) 2002; 97
Paramsothy, Leong (bib14) 2010; 7
Leong, Arshi, Chang (bib16) 2014; 29
Hanauer (bib1) 2006; 12
Geboes, Riddell, Ost (bib12) 2000; 47
Sartor (bib2) 2006; 3
Noth, Stüber, Häsler (bib31) 2012; 6
Kiesslich, Duckworth, Moussata (bib10) 2012; 61
Leong, Wong, Chen (bib11) 2012; 27
Lopez, Ford, Colombel (bib6) 2015; 47
Lovell, Ford (bib24) 2012; 10
Keohane, O'Mahony, O'Mahony (bib25) 2010; 105
Lahiff, Safaie, Awais (bib27) 2013; 37
Baars, Nuij, Oldenburg (bib13) 2012; 18
Halpin, Ford (bib3) 2012; 107
Martínez, Lobo, Pigrau (bib7) 2013; 62
Yang, Leong, Wong (bib18) 2013; 28
Alonso, Guilarte, Vicario (bib33) 2012; 24
Odenwald, Turner (bib22) 2013; 11
Jonefjall, Ohman, Simren (bib5) 2016; 22
Humphris, Swartz, Egan, Leong (bib34) 2012; 33
Liu, Mill, Wong (bib23) 2013; 77
Suenaert, Bulteel, Lemmens (bib30) 2002; 97
Liu, Madsen, Boulanger (bib17) 2011; 45
Accessed August 1, 2015.
Sandborn, Feagan, Marano (bib29) 2014; 146
Fritscher-Ravens (10.1053/j.gastro.2017.05.056_bib9) 2014; 147
Baars (10.1053/j.gastro.2017.05.056_bib13) 2012; 18
Lewis (10.1053/j.gastro.2017.05.056_bib28) 2008; 14
Suenaert (10.1053/j.gastro.2017.05.056_bib30) 2002; 97
Geboes (10.1053/j.gastro.2017.05.056_bib12) 2000; 47
Lovell (10.1053/j.gastro.2017.05.056_bib24) 2012; 10
Leong (10.1053/j.gastro.2017.05.056_bib11) 2012; 27
Kiesslich (10.1053/j.gastro.2017.05.056_bib10) 2012; 61
Liu (10.1053/j.gastro.2017.05.056_bib23) 2013; 77
Martínez (10.1053/j.gastro.2017.05.056_bib7) 2013; 62
Halpin (10.1053/j.gastro.2017.05.056_bib3) 2012; 107
McGuckin (10.1053/j.gastro.2017.05.056_bib8) 2009; 15
Schoepfer (10.1053/j.gastro.2017.05.056_bib26) 2010; 105
Noth (10.1053/j.gastro.2017.05.056_bib31) 2012; 6
Sartor (10.1053/j.gastro.2017.05.056_bib2) 2006; 3
Lahiff (10.1053/j.gastro.2017.05.056_bib27) 2013; 37
Chang (10.1053/j.gastro.2017.05.056_bib15) 2016; 83
Humphris (10.1053/j.gastro.2017.05.056_bib34) 2012; 33
10.1053/j.gastro.2017.05.056_bib21
Hanauer (10.1053/j.gastro.2017.05.056_bib1) 2006; 12
Simrén (10.1053/j.gastro.2017.05.056_bib32) 2002; 97
Vivinus-Nébot (10.1053/j.gastro.2017.05.056_bib20) 2014; 63
Alonso (10.1053/j.gastro.2017.05.056_bib33) 2012; 24
Sandborn (10.1053/j.gastro.2017.05.056_bib29) 2014; 146
Leong (10.1053/j.gastro.2017.05.056_bib16) 2014; 29
Yang (10.1053/j.gastro.2017.05.056_bib18) 2013; 28
Keohane (10.1053/j.gastro.2017.05.056_bib25) 2010; 105
Leong (10.1053/j.gastro.2017.05.056_bib19) 2008; 135
Liu (10.1053/j.gastro.2017.05.056_bib17) 2011; 45
Lopez (10.1053/j.gastro.2017.05.056_bib6) 2015; 47
Odenwald (10.1053/j.gastro.2017.05.056_bib22) 2013; 11
Ballegaard (10.1053/j.gastro.2017.05.056_bib4) 1997; 32
Paramsothy (10.1053/j.gastro.2017.05.056_bib14) 2010; 7
Jonefjall (10.1053/j.gastro.2017.05.056_bib5) 2016; 22
References_xml – volume: 7
  start-page: 366
  year: 2010
  end-page: 368
  ident: bib14
  article-title: Endoscopy: Fluorescein contrast in confocal laser endomicroscopy
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 27
  start-page: 109
  year: 2012
  ident: bib11
  article-title: Intestinal mucosal leakage is detected using in vivo confocal endomicroscopy in macroscopically-normal Crohn's disease and ulcerative colitis
  publication-title: J Gastroenterol Hepatol
– volume: 47
  start-page: 404
  year: 2000
  end-page: 409
  ident: bib12
  article-title: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
  publication-title: Gut
– reference: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0; Mar 2011; Available at:
– volume: 14
  start-page: 1660
  year: 2008
  end-page: 1666
  ident: bib28
  article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
  publication-title: Inflamm Bowel Dis
– volume: 146
  start-page: 96
  year: 2014
  end-page: 109
  ident: bib29
  article-title: PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
  publication-title: Gastroenterology
– volume: 10
  start-page: 712
  year: 2012
  end-page: 721
  ident: bib24
  article-title: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis
  publication-title: Clin Gastroenterol Hepatol
– volume: 37
  start-page: 786
  year: 2013
  end-page: 794
  ident: bib27
  article-title: The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome
  publication-title: Aliment Pharmacol Ther
– volume: 62
  start-page: 1160
  year: 2013
  end-page: 1168
  ident: bib7
  article-title: Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier
  publication-title: Gut
– volume: 107
  start-page: 1474
  year: 2012
  end-page: 1482
  ident: bib3
  article-title: Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis
  publication-title: Am J Gastroenterol
– volume: 18
  start-page: 1634
  year: 2012
  end-page: 1640
  ident: bib13
  article-title: Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation
  publication-title: Inflamm Bowel Dis
– volume: 3
  start-page: 390
  year: 2006
  end-page: 407
  ident: bib2
  article-title: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis
  publication-title: Nat Clin Pract Gastroenterol Hepatol
– volume: 47
  start-page: 356
  year: 2015
  end-page: 364
  ident: bib6
  article-title: Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials
  publication-title: Dig Liver Dis
– volume: 12
  start-page: S3
  year: 2006
  end-page: S9
  ident: bib1
  article-title: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities
  publication-title: Inflamm Bowel Dis
– volume: 33
  start-page: 9
  year: 2012
  end-page: 20
  ident: bib34
  article-title: Status of confocal laser endomicroscopy in gastrointestinal disease
  publication-title: Trop Gastroenterol
– volume: 97
  start-page: 389
  year: 2002
  end-page: 396
  ident: bib32
  article-title: Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors
  publication-title: Am J Gastroenterol
– volume: 77
  start-page: S206
  year: 2013
  ident: bib23
  article-title: Intestinal barrier dysfunction measured with confocal endomicroscopy in macroscopically normal mucosa can predict requirement for treatment escalation
  publication-title: Gastrointest Endosc
– volume: 105
  start-page: 162
  year: 2010
  end-page: 169
  ident: bib26
  article-title: Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI
  publication-title: Am J Gastroenterol
– volume: 11
  start-page: 1075
  year: 2013
  end-page: 1083
  ident: bib22
  article-title: Intestinal permeability defects: is it time to treat?
  publication-title: Clin Gasroenterol Hepatol
– volume: 29
  start-page: 11
  year: 2014
  ident: bib16
  article-title: Acute tumour necrosis factor administration induces transient epithelial cell shedding, mucosal leak and neutrophil recruitment to the gut in a mouse model
  publication-title: J Gastroenterol Hepatol
– volume: 28
  start-page: 28
  year: 2013
  ident: bib18
  article-title: Intestinal barrier dysfunction as identified by confocal endomicroscopy in macroscopically normal terminal is useful in detecting inflammatory bowel disease and predicting requirements for treatment escalation [abstract]
  publication-title: J Gastroenterol Hepatol
– reference: . Accessed August 1, 2015.
– volume: 15
  start-page: 100
  year: 2009
  end-page: 113
  ident: bib8
  article-title: Intestinal barrier dysfunction in inflammatory bowel diseases
  publication-title: Inflamm Bowel Dis
– volume: 135
  start-page: 1870
  year: 2008
  end-page: 1876
  ident: bib19
  article-title: In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease
  publication-title: Gastroenterology
– volume: 83
  start-page: 785
  year: 2016
  end-page: 791
  ident: bib15
  article-title: The learning curve, interobserver, and intraobserver agreement of endoscopic confocal laser endomicroscopy in the assessment of mucosal barrier defects
  publication-title: Gastrointest Endosc
– volume: 6
  start-page: 464
  year: 2012
  end-page: 469
  ident: bib31
  article-title: Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease
  publication-title: J Crohns Colitis
– volume: 45
  start-page: 240
  year: 2011
  end-page: 245
  ident: bib17
  article-title: Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease
  publication-title: J Clin Gastroenterol
– volume: 24
  start-page: 740
  year: 2012
  end-page: 746
  ident: bib33
  article-title: Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability
  publication-title: Neurogastroenterol Motil
– volume: 97
  start-page: 2000
  year: 2002
  end-page: 2004
  ident: bib30
  article-title: Anti–tumor necrosis factor treatment restores the gut barrier in Crohn’s disease
  publication-title: Am J Gastroenterol
– volume: 22
  start-page: 2630
  year: 2016
  end-page: 2640
  ident: bib5
  article-title: IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being
  publication-title: Inflamm Bowel Dis
– volume: 61
  start-page: 1146
  year: 2012
  end-page: 1153
  ident: bib10
  article-title: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
  publication-title: Gut
– volume: 105
  start-page: 1789
  year: 2010
  end-page: 1794
  ident: bib25
  article-title: Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
  publication-title: Am J Gastroenterol
– volume: 32
  start-page: 569
  year: 1997
  end-page: 571
  ident: bib4
  article-title: Self-reported food intolerance in chronic inflammatory bowel disease
  publication-title: Scand J Gastroenterol
– volume: 147
  start-page: 1012
  year: 2014
  end-page: 1020
  ident: bib9
  article-title: Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome
  publication-title: Gastroenterology
– volume: 63
  start-page: 744
  year: 2014
  end-page: 752
  ident: bib20
  article-title: Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation
  publication-title: Gut
– volume: 32
  start-page: 569
  year: 1997
  ident: 10.1053/j.gastro.2017.05.056_bib4
  article-title: Self-reported food intolerance in chronic inflammatory bowel disease
  publication-title: Scand J Gastroenterol
  doi: 10.3109/00365529709025101
– ident: 10.1053/j.gastro.2017.05.056_bib21
– volume: 97
  start-page: 389
  year: 2002
  ident: 10.1053/j.gastro.2017.05.056_bib32
  article-title: Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors
  publication-title: Am J Gastroenterol
  doi: 10.1016/S0002-9270(01)04037-0
– volume: 63
  start-page: 744
  year: 2014
  ident: 10.1053/j.gastro.2017.05.056_bib20
  article-title: Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-304066
– volume: 27
  start-page: 109
  issue: Suppl 4
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib11
  article-title: Intestinal mucosal leakage is detected using in vivo confocal endomicroscopy in macroscopically-normal Crohn's disease and ulcerative colitis
  publication-title: J Gastroenterol Hepatol
– volume: 146
  start-page: 96
  year: 2014
  ident: 10.1053/j.gastro.2017.05.056_bib29
  article-title: PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.06.010
– volume: 3
  start-page: 390
  year: 2006
  ident: 10.1053/j.gastro.2017.05.056_bib2
  article-title: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis
  publication-title: Nat Clin Pract Gastroenterol Hepatol
  doi: 10.1038/ncpgasthep0528
– volume: 29
  start-page: 11
  issue: Suppl 2
  year: 2014
  ident: 10.1053/j.gastro.2017.05.056_bib16
  article-title: Acute tumour necrosis factor administration induces transient epithelial cell shedding, mucosal leak and neutrophil recruitment to the gut in a mouse model
  publication-title: J Gastroenterol Hepatol
– volume: 45
  start-page: 240
  year: 2011
  ident: 10.1053/j.gastro.2017.05.056_bib17
  article-title: Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease
  publication-title: J Clin Gastroenterol
  doi: 10.1097/MCG.0b013e3181fbdb8a
– volume: 33
  start-page: 9
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib34
  article-title: Status of confocal laser endomicroscopy in gastrointestinal disease
  publication-title: Trop Gastroenterol
  doi: 10.7869/tg.2012.3
– volume: 47
  start-page: 404
  year: 2000
  ident: 10.1053/j.gastro.2017.05.056_bib12
  article-title: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
  publication-title: Gut
  doi: 10.1136/gut.47.3.404
– volume: 83
  start-page: 785
  year: 2016
  ident: 10.1053/j.gastro.2017.05.056_bib15
  article-title: The learning curve, interobserver, and intraobserver agreement of endoscopic confocal laser endomicroscopy in the assessment of mucosal barrier defects
  publication-title: Gastrointest Endosc
  doi: 10.1016/j.gie.2015.08.045
– volume: 107
  start-page: 1474
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib3
  article-title: Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2012.260
– volume: 22
  start-page: 2630
  year: 2016
  ident: 10.1053/j.gastro.2017.05.056_bib5
  article-title: IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/MIB.0000000000000921
– volume: 62
  start-page: 1160
  year: 2013
  ident: 10.1053/j.gastro.2017.05.056_bib7
  article-title: Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-302093
– volume: 147
  start-page: 1012
  year: 2014
  ident: 10.1053/j.gastro.2017.05.056_bib9
  article-title: Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.07.046
– volume: 61
  start-page: 1146
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib10
  article-title: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
  publication-title: Gut
  doi: 10.1136/gutjnl-2011-300695
– volume: 7
  start-page: 366
  year: 2010
  ident: 10.1053/j.gastro.2017.05.056_bib14
  article-title: Endoscopy: Fluorescein contrast in confocal laser endomicroscopy
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2010.83
– volume: 15
  start-page: 100
  year: 2009
  ident: 10.1053/j.gastro.2017.05.056_bib8
  article-title: Intestinal barrier dysfunction in inflammatory bowel diseases
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.20539
– volume: 11
  start-page: 1075
  year: 2013
  ident: 10.1053/j.gastro.2017.05.056_bib22
  article-title: Intestinal permeability defects: is it time to treat?
  publication-title: Clin Gasroenterol Hepatol
  doi: 10.1016/j.cgh.2013.07.001
– volume: 47
  start-page: 356
  year: 2015
  ident: 10.1053/j.gastro.2017.05.056_bib6
  article-title: Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials
  publication-title: Dig Liver Dis
  doi: 10.1016/j.dld.2015.01.148
– volume: 97
  start-page: 2000
  year: 2002
  ident: 10.1053/j.gastro.2017.05.056_bib30
  article-title: Anti–tumor necrosis factor treatment restores the gut barrier in Crohn’s disease
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2002.05914.x
– volume: 77
  start-page: S206
  year: 2013
  ident: 10.1053/j.gastro.2017.05.056_bib23
  article-title: Intestinal barrier dysfunction measured with confocal endomicroscopy in macroscopically normal mucosa can predict requirement for treatment escalation
  publication-title: Gastrointest Endosc
  doi: 10.1016/j.gie.2013.04.042
– volume: 10
  start-page: 712
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib24
  article-title: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2012.02.029
– volume: 12
  start-page: S3
  issue: Suppl 1
  year: 2006
  ident: 10.1053/j.gastro.2017.05.056_bib1
  article-title: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/01.MIB.0000195385.19268.68
– volume: 6
  start-page: 464
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib31
  article-title: Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2011.10.004
– volume: 105
  start-page: 162
  year: 2010
  ident: 10.1053/j.gastro.2017.05.056_bib26
  article-title: Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2009.545
– volume: 37
  start-page: 786
  year: 2013
  ident: 10.1053/j.gastro.2017.05.056_bib27
  article-title: The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.12262
– volume: 14
  start-page: 1660
  year: 2008
  ident: 10.1053/j.gastro.2017.05.056_bib28
  article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.20520
– volume: 18
  start-page: 1634
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib13
  article-title: Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.21925
– volume: 24
  start-page: 740
  year: 2012
  ident: 10.1053/j.gastro.2017.05.056_bib33
  article-title: Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability
  publication-title: Neurogastroenterol Motil
  doi: 10.1111/j.1365-2982.2012.01928.x
– volume: 28
  start-page: 28
  issue: Suppl 2
  year: 2013
  ident: 10.1053/j.gastro.2017.05.056_bib18
  article-title: Intestinal barrier dysfunction as identified by confocal endomicroscopy in macroscopically normal terminal is useful in detecting inflammatory bowel disease and predicting requirements for treatment escalation [abstract]
  publication-title: J Gastroenterol Hepatol
– volume: 135
  start-page: 1870
  year: 2008
  ident: 10.1053/j.gastro.2017.05.056_bib19
  article-title: In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.08.054
– volume: 105
  start-page: 1789
  year: 2010
  ident: 10.1053/j.gastro.2017.05.056_bib25
  article-title: Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2010.156
SSID ssj0009381
Score 2.6161919
Snippet Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing. We investigated whether...
Abstract Background & Aims Many patients with inflammatory bowel diseases (IBD) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 723
SubjectTerms Adult
Blood Sedimentation
C-Reactive Protein - metabolism
Case-Control Studies
CLE
Colitis, Ulcerative - diagnostic imaging
Colitis, Ulcerative - physiopathology
Colonoscopy
Crohn Disease - diagnostic imaging
Crohn Disease - physiopathology
Female
Gastroenterology and Hepatology
Humans
Intestinal Barrier Function
Intestinal Mucosa - metabolism
Intravital Microscopy
Leaky Gut
Male
Microscopy, Confocal
Middle Aged
Permeability
Prospective Studies
Severity of Illness Index
Small Intestine
Symptom Assessment
Wound Healing
Title Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0016508517357311
https://www.clinicalkey.es/playcontent/1-s2.0-S0016508517357311
https://dx.doi.org/10.1053/j.gastro.2017.05.056
https://www.ncbi.nlm.nih.gov/pubmed/28601482
https://www.proquest.com/docview/1908793928
Volume 153
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFeEHfKTUbircpwLo6Tx23ANsRgYhvszUpdewytSdWmQvAD-Cn8Ts6J7SaIVhtIVVUlcaL0fPa5-PNnQl7oMFHKhBpyk7AIkkjkwWhsVJDCaJipECljWO84eJ_unSRvT_lpr_erw1pa1KNN9WPlupL_sSocA7viKtl_sOzypnAAfoN94RssDN9XsvE-9OVzJJBjXQ_6KkaWhzDUaiu-jb29tDtaWSGHD-VZhaWB7eqbvhgefZ9M62rSEGIPrbwqsmHrL3A7A0CZ2Al4e_ErO5FjeRnIcneixN7zufh2t5jXswp1PmdW3GnFZj_DME-69d0dX7PGyeaWIOS4wh8XUz2rh8tS0Odi3lQiG4IueDdI9dtK7_7Urj9q9jDvFjTASXrGFvgjNwijajYL_xylraawg2PcGXOFXbD8ly9gzYYeXzfPmjdHFp8VabVC5h14TCcNPqIsxfJq1HrGJV_Rn7pGNiJIR6I-2djdfvdpq5V3hsDHL8zk8ctVD0XZaXebdTHQuhyniXWOb5GbLkmhWxZxt0lPl3fI9QNHw7hLfnrg0RZ4tAs82gEerSvqgEcbLFEPPHpeUg88isCjXeC5ix3wKACPOuBRB7x75OTN6-OdvcBt6BGoRLA64KaAbCRVRRFpDZGiMhDtpsKMdRxBqKxMnuVCJ0YYrZkKc5VoFo4yBkkI11pl8X3SL6tSPyRUQBRlsmJcxEWcMD3OjWC4d1GquRnziA9I7P9iqZzaPW66ciEb1gWPIeu1NpJoI8k4fNIBCZatplbt5ZLrubee9CuZwfdKgOAl7cSqdnruBpe5DOU8kkweYUrGMS0SMRdxGHZbuhjZxr5XeOZzDy8JLgTnBYtSVwt4Vs4ycNN5lA3IA4u75dt7yD5ae-YxudH24iekX88W-ikE6vXomeslvwHEBOvG
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impaired+Intestinal+Permeability+Contributes+to+Ongoing+Bowel+Symptoms+in+Patients+With+Inflammatory+Bowel+Disease+and+Mucosal+Healing&rft.jtitle=Gastroenterology+%28New+York%2C+N.Y.+1943%29&rft.au=Chang%2C+Jeff&rft.au=Leong%2C+Rupert+W&rft.au=Wasinger%2C+Valerie+C&rft.au=Ip%2C+Matthew&rft.date=2017-09-01&rft.eissn=1528-0012&rft.volume=153&rft.issue=3&rft.spage=723&rft_id=info:doi/10.1053%2Fj.gastro.2017.05.056&rft_id=info%3Apmid%2F28601482&rft.externalDocID=28601482
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0016-5085&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0016-5085&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0016-5085&client=summon